The Search For Identity

For OTC derivatives transactions, market participants seeing more challenges beyond just regulatory reporting demands

Bill Stenning, managing director, clearing, regulatory and strategic affairs, Societe Generale

The regulatory push since 2008 concerning the clearing of over-the-counter derivatives has fundamentally changed the industry, and the recent debate about identifiers for these instruments misses what should be the real focus of regulation, experts say.

Joshua Satten, Napa, Calif.-based consultant at Sapient Global Markets (and formerly an OTC products executive at Northern Trust), says that historically, OTC derivatives were traded bilaterally. But in cleared markets, the central counterparty

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact [email protected] or view our subscription options here:

You are currently unable to copy this content. Please contact [email protected] to find out more.

To continue reading...

You need to sign in to use this feature. If you don’t have a WatersTechnology account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here: